Veracyte, Inc.VCYTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +20.81% | +18.20% | +13.75% | +13.82% | +18.55% |
| Gross Profit Growth | +14.43% | +27.28% | +15.22% | +15.53% | +32.92% |
| EBITDA Growth | +0.00% | +236.74% | -48.56% | +6.28% | +373.72% |
| Operating Income Growth | +0.00% | +0.00% | -214.37% | +90.95% | +521.32% |
| Net Income Growth | +0.00% | +0.00% | -117.09% | +26.28% | +704.79% |
| EPS Growth | +0.00% | +0.00% | -117.86% | +20.00% | +642.86% |
| EPS Diluted Growth | +0.00% | +0.00% | -117.86% | +26.32% | +733.33% |
| Weighted Average Shares Growth | +6.16% | +4.37% | +2.19% | +2.22% | +2.02% |
| Weighted Average Shares Diluted Growth | +9.30% | +7.08% | +3.55% | +1.56% | +1.85% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +57.69% | +0.00% | +13.63% | +49.37% | +114.41% |
| Free Cash Flow Growth | +56.13% | +0.00% | +20.57% | +51.38% | +136.81% |
| Receivables Growth | +15.22% | +15.25% | +1.01% | -2.01% | -4.01% |
| Inventory Growth | +34.86% | +32.33% | +29.92% | -0.18% | -5.54% |
| Asset Growth | +16.60% | +9.61% | +8.89% | +7.28% | +8.15% |
| Book Value per Share Growth | +6.10% | +2.35% | +5.51% | +4.62% | +9.15% |
| Debt Growth | +301.72% | +259.69% | +144.22% | +105.41% | -21.84% |
| R&D Expense Growth | +3.30% | +10.99% | -1.22% | -9.06% | +8.08% |
| SG&A Expenses Growth | +13.69% | +20.69% | +4.88% | +7.32% | -19.11% |